The team's results, published in Nature Communications, reveal that the RMIT-patented biomarkers – easily identified through a simple blood test – may be a better guide to who'll potentially benefit ...

Simple information already gathered during routine well-baby visits could help clinicians spot which infants are at risk for persistent developmental delays, without the need for complex testing.

Tirzepatide, semaglutide, and liraglutide vs DPP4i were associated with lower risk of alcohol use disorder, especially among men and younger patients.